---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-153393"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T09:56:31.543121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology enters co-promotion agreement with Kyowa Kirin for ziftomenib in AML

## Summary
- Co-promotion and medical affairs agreement with Kyowa Kirin US for ziftomenib, a menin inhibitor for AML, dated June 27, 2025.
- Kyowa Kirin US will co-promote for up to a certain percentage of US details; parties share costs equally.
- Kura leads US medical affairs; parties jointly develop health economics and outcomes research strategy.
- Term continues until mutual cessation of US commercialization or expiration of Collaboration Agreement term (up to 10 years after first commercial sale).
- Agreement automatically terminates with Collaboration Agreement; either party can terminate for uncured material breach.

## SEC filing metadata
- accession: 0001193125-25-153393
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525153393/0001193125-25-153393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525153393/d911089d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-153393
- JSON: https://secwatch.observer/filing/0001193125-25-153393.json
- Plain text: https://secwatch.observer/filing/0001193125-25-153393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.